甲状旁腺激素(1-34)联合伊班膦酸钠治疗严重骨质疏松症的临床研究被引量：3

Clinical study of parathyroid hormone( 1-34) combined with ibandronate in the treatment of serious postmenopausal osteoporosis

下载PDF

导出

摘要目的甲状旁腺激素(parathyroid hormone,PTH)(1-34)联合伊班膦酸钠治疗严重骨质疏松症效果临床观察。方法98例严重绝经后骨质疏松症合并骨骼疼痛患者随机分为治疗组和对照组,治疗组使用PTH联合伊班膦酸钠治疗,对照组单纯予以伊班膦酸钠治疗,为期12个月。分别检测两组受试者腰椎及髋部骨密度、血清骨代谢指标治疗前后的改变。结果药物治疗6个月后两组患者腰椎L1~4及股骨粗隆、左侧股骨颈、Ward三角区的骨密度明显增加,且12个月后骨密度进一步增加,显著高于对照组(P<0.05);药物治疗12个月后两组血清及碱性磷酸酶(ALP)、血清Ⅰ型胶原C末端肽(s-CTX)、血清抗酒石酸酸性磷酸酶-5b(TRACP-5b)、血清骨源性碱性磷酸酶(BAP)及血清骨钙素(OC)水平均显著改变,且治疗组对ALP及s-CTX、BAP、OC及TRACP-5b影响更明显(P<0.05),而两组血钙(Ca)及血磷(P)治疗前后无明显差异(P>0.05)。结论PTH联合伊班膦酸钠使用能有效提高严重骨质疏松症患者髋部及腰椎骨密度,改善骨代谢。 Objective To observe the effect of parathyroid hormone（ 1-34,PTH） combined with ibandronate sodium on serious postmenopausal osteoporosis. Methods 98 patients with serious postmenopausal osteoporosis and bone pain were randomly divided into treatment group and control group. The treatment group was treated with PTH combined with ibandronate,and the control group was treated with ibandronate sodium for 12 months. The changes of bone mineral density and serum bone metabolic index were measured before and after treatment. Results In both groups,bone density of lumbar vertebrae L1-4,proximal femur,left femoral neck and Ward triangle increased significantly after 6 months of intervention,and further increased after 12 months,with greater effects in the combined treatment group than in the control group（ P 〈 0. 05）. After 12 months of intervention,the levels of serum alkaline phosphatase（ ALP）,serum type I collagen C-terminal peptide（ s-CTX）,serum anti-tartrate acid phosphatase-5 b（ TRACP-5 b） and serum osteocalcin（ OC） changed significantly,and the changes in ALP,s-CTX,BAP,OC and TRACP-5 b were greater in the treatment group compared with that of the control group（ P 〈 0. 05）. There were no significant differences between the two groups in the concentrations of serum Ca and phosphorus（ P） before and after treatment（ P 〉 0. 05）.Conclusion PTH combined with ibandronate can effectively protect hip and lumbar vertebrae bone mineral density and improve bone metabolism in serious postmenopausal osteoporosis.

作者汪大伟丁一何成龙赵伟峰 WANG Dawei;DING Yi;HE Chenglong;ZHAO Weifeng(Guizhou Medical University, Guiyang 550000, China;Guizhou Provincial People＇ s Hospital, Guiyang 550002, China)

机构地区贵州医科大学贵州医科大学附属贵州省人民医院

出处《中国骨质疏松杂志》 CAS CSCD 北大核心 2018年第5期641-644,共4页 Chinese Journal of Osteoporosis

关键词甲状旁腺激素(1-34) 伊班膦酸钠绝经后骨质疏松症骨密度骨代谢 Parathyroid hormone（1-34） Ibandronate Postmenopausal osteoporosis Bone mineral density Bone metabolism

分类号 R681 [医药卫生—骨科学]

引文网络
相关文献

参考文献1

1刘海蔚,严励,高勇义,陈开宁,方团育,张华川,陈道雄,全会标,陈赛语.重组人甲状旁腺素(1-34)对绝经后妇女骨质疏松症治疗的有效性及对骨代谢标志物水平的影响[J].现代预防医学,2014,41(8):1490-1493. 被引量：6

二级参考文献14

1邱贵兴.骨质疏松性骨折——被忽视了的健康杀手[J].中华医学杂志,2005,85(11):730-731. 被引量：76
2Cosman F. Parathyroid hormone treatment for osteoporosis [J]. Curr Opin Endocrinol Diabetes Obes, 2008, 15 (6) : 495-501.
3Thomas T. Intermittent parathyroid hormone therapy to increase bone formation [J]. Joint Bone Spine, 2006, 73 (3) : 262-269.
4Paschalis EP, Glass EV, Donley DW, et al. Bone mineral and col- lagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trim [J]. J Clin Endocrinol Metab, 2005, 90 (8): 4644-4649.
5Miyauchi A, Matsumoto T, Shigeta H, et al. Effect of teriparatide on bone mineral density and biochemical markers in Japanese womenwith postmenopausal osteoporosis: a 6-month dose-response study [J]. J Bone Miner Metab, 2008, 26 (6) : 624-634.
6Neer RM, Amaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post- menopausal women with osteoporosis [J]. N Engl J Med, 2001, 344 (19): 1434-1441.
7Eastell R, Nickelsen T, Matin F, et al. Sequential treatment of se- vere postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EURO- FORS)[J]. J Bone Miner Res, 2009, 24 (4) : 726-736.
8Kung AW, Pasion EG, Sofiyan M, et el. A comparison of teri- paratide and celcitonin therapy in postmenopausal Asian women with osteoporosis: a6-month study [J]. Curr Med Res Opin, 2006, 22 (5) : 929-937.
9Hwang JS, Tu ST, Yang TS, et el. Teriparatide vs. celcitonin in the treatment of Asian postmenopausel women with established osteo- porosis [Jl. Osteoporos Int, 2006, 17 (3) : 373-378.
10Andrews EB, Gilsenan AW, MidkiffK, et al. The US postmarket- ing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years [J]. J Bone Miner Res, 2012, 27 (12): 2429-2437.